阿法骨化醇对大剂量糖皮质激素治疗肾小球疾病所致的骨质疏松的影响

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (4): 446-448.

阿法骨化醇对大剂量糖皮质激素治疗肾小球疾病所致的骨质疏松的影响

于长青, 王可平, 杭宏东, 谢华, 李龙凯, 王静

大连医科大学附属第一医院肾内科,大连 116011,辽宁

收稿日期:2010-02-26 修回日期:2010-03-20 发布日期:2020-09-17
作者简介:于长青,男,硕士研究生,副主任医师,研究方向:慢性肾小球肾炎及血液净化远期并发症的防治。Tel: 0411-83635963-7147 E-mail:yuchq@sina.com

Effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients

YU Chang-qing, WANG Ke-ping, HANG Hong-dong, XIE Hua, LI Long-kai, WANG Jing

Department of Nephrology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, Liaoning, China

Received:2010-02-26 Revised:2010-03-20 Published:2020-09-17

摘要/Abstract

摘要： 目的: 观察阿法骨化醇联合钙剂对肾脏病患者发生糖皮质激素性骨质疏松的预防作用。方法: 28例病人随机分为治疗组16例,阿法骨化醇 1 μg 日一次口服和碳酸钙 750 mg 日三次口服;对照组12例,碳酸钙 750 mg 日三次口服。治疗前及以后每3个月检查血清白蛋白、钙、磷、24小时尿蛋白定量、甲状旁腺素,腰椎和股骨颈骨密度,观察6个月。结果: 两组患者腰椎和股骨颈骨密度均呈下降趋势,治疗6个月时,治疗组骨密度高于对照组(腰椎 0.967±0.105,0.896±0.131, P<0.05;股骨颈 1.078±0.124, 0.925±0.107,P<0.05),对照组骨密度较治疗前明显下降。结论: 阿法骨化醇合用钙剂对预防慢性肾脏病患者发生糖皮质激素性骨质疏松是安全有效的药物。

关键词: 阿法骨化醇, 糖皮质激素, 肾小球疾病, 骨密度

Abstract: AIM:To observe the effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients. METHODS: 28 patients with glomerulonephritis receiving glucocorticoids were divided into two groups randomly. 16 patients received calcium carbonate 750 mg three times plus alfacalcidol 1 μg one time orally a day (treatment group), and 12 patients received calcium carbonate 750 mg three times orally a day (control group). Bone mineral density (BMD) in the lumbar spine (L2-4) and the femoral neck were measured by dual-energy X-ray absorptiometry (DEXA). Intact parathyroid hormone (iPTH), serum albumin (ALB), serum calcium and phosphorus were detected before and 3, 6 months after treatment. RESULTS: BMD in the treatment group at the sixth month were higher than control group (lumbar spine 0.967±0.105, 0.896±0.131, P<0.05; femoral neck 1.078±0.124, 0.925±0.107, P<0.05). BMD in the control group at the sixth month were lower than those before treatment. There were no statistical differences in iPTH, ALB, serum calcium and phosphorus in two groups before and 3, 6 months after therapy. CONCLUSION: Alfacalcidol can decrease loss of bone mass in the lumbar spine and the femoral neck in the glomerulonephritis patients receiving glucocorticoid therapy.

Key words: Alfacalcidol, Glucocorticoid, Glomerulonephritis, Bone mineral density

中图分类号:

R692

于长青, 王可平, 杭宏东, 谢华, 李龙凯, 王静. 阿法骨化醇对大剂量糖皮质激素治疗肾小球疾病所致的骨质疏松的影响[J]. 中国临床药理学与治疗学, 2010, 15(4): 446-448.

YU Chang-qing, WANG Ke-ping, HANG Hong-dong, XIE Hua, LI Long-kai, WANG Jing. Effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 446-448.

参考文献

[1] Van Staa TP, Lenfkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fracture[J]. J Bone Miner Res, 2000, 15(6): 993-1000.
[2] Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy[J]. Calcif Tissue Int, 2000, 66(3): 195-199.
[3] Yonemura K, Kimura M, Miyaji T, et al. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patient with chronic glomerulonephritis[J]. Calcif Tissue Int, 2000, 66(2): 123-128.
[4] Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis[J]. Osteoporosi Int,1999, 9(1): 75-81.
[5] Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis[J]. Ann Rheum Dis, 1995, 54(10): 801-806.
[6] van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy[J]. Arthritis Rheum, 2003, 48(11): 3224-3229.
[7] Hong D, Chen HX, Ge RS, et al. The biological roles of extracellular and intracytoplasmic glucocorticoids in skeletal cells[J]. J Steroid Biochem Mol Biol, 2008, 111(3): 164-170.
[8] Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy[J]. Osteoporos Int, 2007, 8(10): 1319-28.
[9] Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast[J]. J Clin Invest, 2006, 116(8): 2152-2160.
[10] Azuma K, Urano T, Ouchi Y, et al. Glucocorticoid-induced gene tripartite motif-containing 63 (TRIM63) promotes differentiation of osteoblastic cells[J]. Endocr J,2010, 20(2):1-8.
[11] Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach[J]. Arthritis Rheum, 1999, 42(8): 1740-1751.
[12] 陈航,王梅. 原发性肾小球疾病糖皮质激素性骨质疏松预防治疗的临床研究[J]. 中华医学杂志,2005,85(31):2207-2210.
[13] 丁晓凯,刘毅,徐玉兰,等. 钙维生素D复合物单独与联用阿仑膦酸钠在治疗糖皮质激素引起骨量丢失疗效的观察[J]. 中国临床药理学与治疗学,2009,14(3):332-336.

[1]	赵阳婷, 陈重阳, 潘斌晶, 吕小羽, 刘靖芳. 三甲胺N-氧化物：骨质疏松治疗的潜在靶点[J]. 中国临床药理学与治疗学, 2023, 28(10): 1161-1167.
[2]	王梦文, 郭艳, 王重阳, 陶福林, 朱文涛, 韩智莉, 孙念霞, 李泽庚, 汪电雷. 化痰降气胶囊含药血清调控Nrf2/HDAC2改善16HBE细胞糖皮质激素抵抗[J]. 中国临床药理学与治疗学, 2021, 26(12): 1360-1369.
[3]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[4]	俞陈陈，刘树群，刘建龙，曹红，刘雪娇，蔡茜茜. 姜黄素对高血压病大鼠全脑缺血再灌注时海马神经元损伤及皮质酮、SGK1表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(7): 737-743.
[5]	张丹阳，董晓敏，周晓焕，张越，张娟，周合冰. 基于GEO数据库筛查急性淋巴细胞白血病糖皮质激素耐药相关基因[J]. 中国临床药理学与治疗学, 2019, 24(3): 272-277.
[6]	薛骅，鲁丽利，向辉，钱振华. 乌司他丁联合氢化可的松治疗重症脓毒血症休克的疗效及对血清因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(3): 313-317.
[7]	贺筱彬，林小华，刘舜莉，欧焕娇. 血嗜酸性粒细胞水平影响慢性阻塞性肺疾病急性加重患者使用全身糖皮质激素的药物利用评价[J]. 中国临床药理学与治疗学, 2019, 24(1): 89-93.
[8]	卢晓红，王培光. 皮肌炎治疗研究进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 836-840.
[9]	史德军，刘义. 不同剂量二甲双胍对老年2型糖尿病男性患者骨密度和骨代谢的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1045-1049.
[10]	宋美情. 二甲双胍对2型糖尿病伴高血压患者骨密度及胰岛素抵抗、细胞因子的影响[J]. 中国临床药理学与治疗学, 2017, 22(6): 694-698.
[11]	张军，谢艳云，李智，陶立坚. 剪接因子SRp40调控糖皮质激素受体α/β的表达及其对肾病综合征患者糖皮质激素疗效的影响[J]. 中国临床药理学与治疗学, 2017, 22(5): 589-593.
[12]	商宏恺，傅爱萍，陈露芳，仝进毅，斯奇. 地塞米松对人胎盘葡萄糖转运功能的作用及机制[J]. 中国临床药理学与治疗学, 2017, 22(11): 1221-1226.
[13]	杨琴，杜青，赵洪庆，王宇红，韩远山，杨蕙，孟盼 . 百合疏肝安神汤对焦虑性抑郁症模型大鼠前额叶-边缘结构及GR/BDNF/NPY表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(10): 1090-1098.
[14]	陈丽思，黄志荣，吴海游，许碧莲，崔燎，吴铁，邹丽宜. 辅酶Q10对去卵巢大鼠骨质和骨密度的影响[J]. 中国临床药理学与治疗学, 2016, 21(8): 868-872.
[15]	韦柳萍，宋林，杨彬. 联合吸入噻托溴铵与糖皮质激素/长效β₂受体激动剂治疗稳定期慢性阻塞性肺疾病有效性和安全性的系统评价[J]. 中国临床药理学与治疗学, 2016, 21(7): 777-783.